Active Volume Stock: Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cornelia Mascio
Febbraio 23, 2018

Commerzbank Aktiengesellschaft FI lifted its stake in shares of Teva Pharmaceutical Industries by 116.2% in the 4th quarter. The fund owned 51,034 shares of the company's stock after selling 30,338 shares during the period. Finally, Global Financial Private Capital LLC acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $193,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Mackenzie Financial Corp lifted its stake in shares of Teva Pharmaceutical Industries by 419.6% in the 3rd quarter. While talking about Performance of the Stock, Teva Pharmaceutical Industries Limited now has a Weekly performance of 8.48%, monthly performance percentage is -4.42 percent, Quarterly performance is 45.16 percent, 6 months performance shows a percent value of 17.9% and Yearly Performance is -45.18 percent. M&T Bank Corp's holdings in Teva Pharmaceutical Industries were worth $734,000 at the end of the most recent quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Schroder Investment Management Group now owns 6,194,083 shares of the company's stock worth $106,290,000 after acquiring an additional 1,147,683 shares during the period.

Want to see what other hedge funds are holding TEVA? Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Teva Pharmaceutical Industries by 1.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company's stock worth $3,755,000 after purchasing an additional 3,100 shares during the period. Investors measure stock performance on the basis of a company's earnings power.

In other news, EVP Mark Sabag sold 5,050 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The stock has an average rating of "Hold" and an average price target of $21.26. Following the transaction, the executive vice president now owns 44,517 shares in the company, valued at approximately $876,094.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of equities research analysts have recently issued reports on TEVA shares. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an "underperform" rating for the company in a research report on Friday, February 9th. Credit Suisse Group reiterated an "underperform" rating and set a $8.00 price target (down from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Wells Fargo & Co reaffirmed a "sell" rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 13th. Royal Bank of Canada set a $11.00 price objective on Teva Pharmaceutical Industries and gave the company a "sell" rating in a research report on Wednesday, November 29th.

This is a summary of current ratings and recommmendations for Innocoll and Teva Pharmaceutical Industries, as reported by

The company's stock is now moving with a -ve distance from the 200 day SMA of approximately -6.08%, and has a solid year to date (YTD) performance of 6.02% which means that the stock is constantly adding to its value from the previous fiscal year end price.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $20.09 on Thursday. The company's market cap is $20.57 Billion, and the average volume is $23.1 Million. The 52-Week High range of the stock is $36.69, while the 52-week low range is $10.85. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. Comparatively, Teva Pharmaceutical Industries Limited posted earnings of $1.2 per share in the same quarter past year.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) gross margin percentage stands at 48.4% while its operating margin for the past trailing twelve month is -78.1 percent and its overall profit margin (ttm) is -73.8 Percent. The firm had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. The company reported revenue of $6 Billion in the same period past year. During the same period last year, the company posted $1.38 EPS. equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.31 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: "Teva Pharmaceutical Industries Ltd (TEVA) Position Trimmed by US Bancorp DE" was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & worldwide trademark and copyright laws. The original version of this article can be accessed at

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE